HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia

Cancer Letters

Volumn 348, Issue 1-2, 2014, Pages 50-60

  Yun, Sun Mi ^a   Jung, Kyung Hee ^a,b   Kim, Soo Jung ^a   Fang, Zhenghuan ^a   Son, Mi Kwon ^a   Yan, Hong Hua ^a   Lee, Hyunseung ^a   Kim, JinHee ^c   Shin, Sanghye ^c   Hong, Sungwoo ^c   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b Chonnam National University   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

BCR ABL; Chronic myeloid leukemia; HS 438; T315I

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; HS 438; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T315I GENE; TUMOR GROWTH; WILD TYPE; XENOGRAFT;

BCR-ABL; CHRONIC MYELOID LEUKEMIA; HS-438; T315I;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BENZOTHIAZOLES; BINDING SITES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; MODELS, MOLECULAR; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS; TUMOR BURDEN; UREA;

EID: 84900466184     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.012     Document Type: Article

References (37)

1. Huang X., Cortes J., Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012, 118:3123-3127.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183.
3. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
4. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453.
5. Tomoda K., Kato J.Y., Tatsumi E., Takahashi T., Matsuo Y., Yoneda-Kato N. The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression. Blood 2005, 105:775-783.
6. Hofmann W.K., Komor M., Wassmann B., Jones L.C., Gschaidmeier H., Hoelzer D., Koeffler H.P., Ottmann O.G. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 2003, 102:659-661.
7. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 5:561-566.
8. O'Hare T., Eide C.A., Deininger M.W. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008, 17:865-878.
9. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
10. Jabbour E., Cortes J., Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: an evidence-based review. Core Evid 2010, 4:207-213.
11. Martinelli G., Iacobucci I., Soverini S., Palandri F., Castagnetti F., Rosti G., Baccarani M. Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. Biologics 2007, 1:121-127.
12. La Rosée P., Corbin A.S., Stoffregen E.P., Deininger M.W., Druker B.J. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002, 62:7149-7153.
13. Hong S., Kim J., Yun S.M., Lee H., Park Y., Hong S.S., Hong S. Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant. J Med Chem 2013, 56:3531-3545.
14. Kaufmann S.H., Hengartner M.O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001, 11:526-534.
15. Witte O.N. Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993, 53:485-489.
16. Kolibaba K.S., Druker B.J. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997, 1333:F217-F248.
17. Hochhaus A., Kreil S., Corbin A.S., La Rosée P., Müller M.C., Lahaye T., Hanfstein B., Schoch C., Cross N.C., Berger U., Gschaidmeier H., Druker B.J., Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
18. Soverini S., Martinelli G., Amabile M., Poerio A., Bianchini M., Rosti G., Pane F., Saglio G., Baccarani M. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004, 50:1205-1213.
19. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M.A., Iyer V., Chen T.T., Huang F., Decillis A.P., Sawyers C.L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
20. Quintás-Cardama A., Kantarjian H., Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6:834-848.
21. Cheetham G.M., Charlton P.A., Golec J.M., Pollard J.R. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007, 251:323-329.
22. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., Reddy M.V., Reddy E.P. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 2005, 102:1992-1997.
23. Zhang H., Trachootham D., Lu W., Carew J., Giles F.J., Keating M.J., Arlinghaus R.B., Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008, 22:1191-1199.
24. Chandra J., Tracy J., Loegering D., Flatten K., Verstovsek S., Beran M., Gorre M., Estrov Z., Donato N., Talpaz M., Sawyers C., Bhalla K., Karp J., Sausville E., Kaufmann S.H. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood 2006, 107:2501-2506.
25. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002, 9:268-272.
26. Young M.A., Shah N.P., Chao L.H., Seeliger M., Milanov Z.V., 3rd Biggs W.H., Treiber D.K., Patel H.K., Zarrinkar P.P., Lockhart D.J., Sawyers C.L., Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006, 66:1007-1014.
27. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-502.
28. Pietenpol J.A., Stewart Z.A. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 2002, 181-182:475-481.
29. Malumbres M., Pevarello P., Barbacid M., Bischoff J.R. CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol Sci 2008, 29:16-21.
30. Yoon M.K., Mitrea D.M., Ou L., Kriwacki R.W. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 2012, 40:981-988.
31. Tateishi Y., Matsumoto A., Kanie T., Hara E., Nakayama K., Nakayama K.I. Development of mice without Cip/Kip CDK inhibitors. Biochem Biophys Res Commun 2012, 427:285-292.
32. Petronilli V., Penzo D., Scorrano L., Bernardi P., Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem 2001, 276:12030-12034.
33. Armstrong J.S. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006, 147:239-248.
34. Kuznetsov A.V., Troppmair J., Sucher R., Hermann M., Saks V., Margreiter R. Mitochondrial subpopulations and heterogeneity revealed by confocal imaging: possible physiological role?. Biochim Biophys Acta 2006, 1757:686-691.
35. Lindsay J., Esposti M.D., Gilmore A.P. Bcl-2 proteins and mitochondria-specificity in membrane targeting for death. Biochim Biophys Acta 1813, 2011:532-539.
36. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995, 146:3-15.
37. Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010, 430:199-205.